American scientists have developed a unique experimental drug for Alzheimer's disease, which could significantly slow the decline in cognitive abilities and also reduce the amount of harmful deposits in the brain in patients with moderate and early forms of the disease. At the moment, any clinical trials.
Since this disease in the world recorded about 15 million people and that number is only growing, the cure for Alzheimer's enough to be expected. However, even if all goes well with the new tool, it will appear on the market no earlier than 2020.
Modern drug was developed by Biogen Idec, whose shares then soared by 50%. In the case of complete success, the producers will receive millions of dollars from drug sales worldwide.
It is worth noting that the first test of the drug began in December last year. Then, it was noted that the reception of a medicament can largely delay the process cognitive impairment in a human patient. But at that time on the overall effectiveness of the drug has been told little.
Repeated testing the results were presented at the conference held in France, which was devoted to the problems of treating Alzheimer's disease. According to the creators adukanumaba, its action is largely surpassed their expectations. Meanwhile, many expressed doubts that the side effects from the use of maximum dose will not harm people's health.
Experts in the treatment of dementia were impressed, but they warn against hasty conclusions, because as far as the first phase of testing, where more questions on security medication. At the same time, everyone understands that tests other similar drugs until proved unsuccessful.
"The results are definitely encouraging” - said Samuel Gandhi of the Center for Cognitive Health in New York, adding that the impact of the maximum dose very impressive.
Adukanumab (BIIB037) was designed specifically to cleanse the brain of amyloid plaques, which are believed to be the cause of memory loss and other negative manifestations of Alzheimer's disease.
Neither large scale clinical trial of other drugs has not led to results.
So, Johnson & Johnson and Pfiser already refused the drug, which is jointly developed, after he did not show results. Some experts believe that such drugs can be successful only if a very early beginning of the reception, when the disease has not progressed.
The first phase of tests performed on adukanumaba 166 patients who were randomly assigned to different doses of the drug or a placebo. The drug not only slows cognitive decline,
but also significantly reduced the number of plaques in the brain, and the higher the dose, the more effective it worked.
Check the results on a more extensive testing company plans this year.